



2026 Annual General Meeting Presentation

23 October 2026

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") advises that the Annual General Meeting ("AGM") will be held today, Friday, 23 October 2026, at 2:00pm (AEST), at the offices of K&L Gates 16/66 Eagle Street, Brisbane City QLD 4000.

Attached is the AGM presentation to be delivered at the 2026 Annual General Meeting

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.



For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com



Annual General Meeting

23 October 2026

AGM Presentation | October 2026

Important Notice and Disclaimer

- ▶ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd (Company or LTP) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While the Company has taken reasonable care in preparing this presentation, no representation is made as to the accuracy or completeness of the material contained in it.
- ▶ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or purchase LTP securities. This presentation is not exhaustive and does not contain all of the information a potential investor, or their professional advisers would require, and it does NOT constitute a "Prospectus" or a "Disclosure Document" (as defined in the Corporations Act 2001 (Cth), and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. This presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed publicly in the United States. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such restrictions could constitute a violation of applicable securities laws.
- ▶ Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.
- ▶ Forward looking statements: This presentation contains forward-looking information about the

Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

- ▶ Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice.
- ▶ [LTR Pharma Limited ACN 644 924 569](#)
- ▶ No New Material Information: This presentation contains no new material information; all information has been previously disclosed in the Company's ASX announcements.

FY26 in review

Key milestones, 1 July 2025 to 30 June 2026

Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Jul to Sep 2025	Oct to Dec 2025	Jan to Mar 2026	Apr to Jun 2026
▶ Dr Amy Pearlman and Dr Andrew Sun join the Scientific Advisory Board ▶ SPONTAN® Phase I data published (EJPS) ▶ 18-month shelf life achieved ▶ 33% interest in LevOmega	▶ Ethics approval and TGA clearance for SPONTAN® Phase II ▶ 1,000 SPONTAN® prescriptions under the TGA Special Access Scheme ▶ LevOmega interest increased to 43%	▶ Phase II recruitment commenced and completed ▶ Phase I data presented at WMSM 2026, Porto (podium) ▶ Positive real-world outcomes in younger men	▶ Phase II interim data: rapid onset, supports FDA pathway ▶ Binding term sheets with Shed Holdings and Strive Pharmacy ▶ OROFLOW® study receives ethics approval

Since year-end

From U.S. agreements to first U.S. prescriptions, July to October 2026

Q1 FY27

Jul to Sep 2026

- **JUL** Definitive U.S. agreements executed with Shed Holdings and Strive Pharmacy
- **AUG** 147-patient real-world study: 93% response in men seeking convenience; 68% overall
- **SEP** KYZATREX® pilot commercialisation agreement with Marius Pharmaceuticals

October 2026

October 2026 to date

- **1 OCT** Final Phase II Clinical Study Report: six-fold faster absorption; FDA PK dataset complete
- **6 OCT** First ROXUS® prescriptions fulfilled in the U.S.
- **21 OCT** SPONTAN surpasses 2,000 dispensed units under TGA's Special Access Scheme (SAS)
- **22 OCT** SPONTAN Ethics Approval for Pulmonary Arterial Hypertension (PAH)

Source: ASX announcements, July to October 2026. These events occurred after the end of FY26 (30 June 2026).

Executive Summary

Clinical validation → Real-world validation → U.S. prescriptions commenced

1

Clinical proof established

- SPONTAN / ROXUS is a rapid-acting intranasal PDE5 therapy. Final Phase II data confirmed six-fold faster median absorption than oral vardenafil ($p < 0.0001$), with a favourable safety and tolerability profile.¹

- Lead program: SPONTAN / ROXUS

6× faster
median absorption

2

Real-world demand validated

- A 147-patient Australian TGA SAS cohort: 93% of men seeking greater convenience and spontaneity reported improved erectile hardness and/or penetration (42 of 45); 68% across the full cohort.²

- Evidence: clinical + patient reported

93%
Response in men seeking
convenience (42 of 45)

3

U.S. prescriptions commenced

- ROXUS patient-specific prescription fulfilment commenced under Shed and Strive (Oct 2026). The FDA pharmacokinetic dataset is complete; pivotal Phase III is targeted for 1H CY2027. \$19.6M cash and zero debt support near-term execution.³
- Commercial partners: Shed, Strive, Aptar, Mayne, EBOS/Symbion

150,000
Minimum ROXUS units Shed
has committed to support

Large ED Market with a Clear Treatment Gap

Oral PDE5 inhibitors remain first-line, but response and persistence limitations leave a sizeable unmet need

~US\$5B

estimated annual global
ED drug market¹

~322M

men globally estimated
to have ED in 2025¹

Treatment pathway and gap

1 Oral PDE5 inhibitors

First-line therapy; delayed onset
and high discontinuation

2 30–35% inadequate response

Higher failure rates in difficult-
to-treat populations²

3 Invasive second-line options

Intracavernosal injection utilisation
has fallen >55-fold from peak³

SPONTAN roXUS

**Rapid-onset,
non-invasive PDE5 option**

- Positioned across the broad ED market
- Supports patients seeking greater spontaneity
- Provides a non-invasive option for patients inadequately served by oral therapy
- Positioned before invasive treatments

PDE5 inhibitors work. Oral delivery is the constraint

Same mechanism; the difference is absorption speed



First-pass metabolism

Oral PDE5is are absorbed through the gut and pass through the liver, where 90 to 95% of the drug is removed before it reaches the circulation.

Higher doses are needed to reach therapeutic levels



30 to 120 minutes to peak

Median Tmax: avanafil 30 min, sildenafil 60 min, vardenafil 60 min, tadalafil 120 min.

Intimacy has to be planned around the tablet



Food, alcohol and the gut

A high-fat meal delays and reduces absorption of sildenafil and vardenafil. Dyspepsia and reflux are common reasons men avoid daily dosing.

Timing rules add friction to an already sensitive moment.

Agent	US brand	Usual on-demand dose	Route	Median Tmax	Half-life
Sildenafil	Viagra®	25, 50, 100 mg	Oral	60 min	~4 h
Vardenafil	Levitra®	10, 20 mg	Oral	60 min	~4 h
Tadalafil	Cialis®	10, 20 mg (5 mg daily)	Oral	120 min	17.5 h
Avanafil	Stendra®	50, 100, 200 mg	Oral	30 min	~5 h
Vardenafil	ROXUS®	5 mg (2.5 mg per nostril)	Intranasal	10 min	~4 h

Final Phase II Report Confirms Six-Fold Faster Absorption and Completes FDA PK Dataset

Final Clinical Study Report | n=27 (14 aged ≥65) | randomised three-way crossover | independent CRO

Key Findings

- ▶ Six-fold faster absorption than oral vardenafil (p<0.0001)
- ▶ Approximately dose-proportional exposure; substantially lower metabolite (M1) exposure than the oral tablet
- ▶ No drug accumulation over five days of once-daily dosing
- ▶ Comparable pharmacokinetics in men aged 65 and over (14 of 27)
- ▶ No SAEs, no Grade 3+ events, no discontinuations; most frequent treatment-related events nasal congestion and headache, mild and self-resolving

Comparative PK results		Six-fold faster absorption, p<0.0001		
Parameter	SPONTAN 5 mg	SPONTAN 2.5 mg	Vardenafil 20 mg oral	
Tmax, median (range)	10 min (10–15)	11 min (5–60)	60 min (30–186)	
Cmax (mean ± SD, ng/mL)	8.9 ± 6.8	5.8 ± 4.9	19.8 ± 8.8	
Half-life (t½, mean)	4.4 hours	3.8 hours	4.4 hours	
Dose-normalised AUC0-inf (ng·h/mL/mg)	3.6	4.8	3.2	
Accumulation ratio (5 days once daily)	1.0 ± 0.9	n.a.	n.a.	
SAEs / Grade 3+ TEAEs / discontinuations	0	0	0	

Design agreed with FDA at Pre-IND. Final report completes the PK dataset for the planned 505(b)(2) submission.

Real-World Outcomes: Patient-Reported Response

Improved erectile hardness and/or achieving penetration | 147 treatment-experienced men

93% men seeking greater convenience and spontaneity (42 of 45)

68% overall cohort (100 of 147)

53% achieved penetration following treatment (78 of 147)

Composite endpoint by subgroup

By reason for seeking treatment and prostatectomy status

57% 58 of 102

Inadequate response to oral PDE5 therapy

64% 56 of 87

Post-prostatectomy subgroup

73% 44 of 60

Non-prostatectomy subgroup

Post-prostatectomy context: oral PDE5i response 12–17% in the first six months²; ED in up to 85% of men¹

Highest response among men seeking greater convenience and spontaneity, with encouraging results in men inadequately served by oral therapy and men following prostatectomy.

ROXUS® U.S. Prescriptions Commenced

First valid patient-specific ROXUS® prescriptions fulfilled by Strive through Mavrox



Demand Engine

Shed Holdings LLC | Executed 17 Jul 2026

US direct-to-consumer telehealth platform: Mavrox

- ▶ First U.S. commercial route-to-market; first valid patient-specific prescriptions received through Mavrox and fulfilled
- ▶ Committed to support a minimum of 150,000 ROXUS® units in the first 12 months from Commercial Launch, underpinning its telehealth exclusivity
- ▶ Two-year U.S. DTC telehealth exclusivity from launch, subject to performance



Supply Engine

Strive Pharmacy | Executed 20 Jul 2026

Exclusive US 503A pharmacy and fulfilment partner

- ▶ Five-state 503A platform with nationwide compounding and fulfilment licensure
- ▶ Technology transfer and readiness complete; approximately 100,000 Aptar pump and bottle components received
- ▶ Two-year exclusivity, subject to performance; LTR retains product ownership, IP and formulation supply



ROXUS® U.S. patient-specific prescription fulfilment has commenced.

- ▶ Moves ROXUS® from U.S. Market preparation to prescription fulfilment
- ▶ Capital-light model using established telehealth and pharmacy infrastructure
- ▶ First patient-specific prescriptions now being fulfilled
- ▶ Premium ED positioning without LTR building U.S. prescribing, pharmacy or fulfilment infrastructure

ASX announcement 6 October 2026

Portfolio Overview and Development Focus

Validated Platform and Expanding Men's Health Portfolio



Lead Clinical Program

SPONTAN **ROXUS**

*Intranasal Sprays for Erectile
Dysfunction*

- ▶ TGA Early Access – ACTIVE
- ▶ FDA 505(b)(2) regulatory pathway
 - ▶ Phase II PK study complete; final report completes FDA PK dataset
- ▶ U.S. ROXUS prescription fulfilment commenced (Oct 2026)

Early Development

OROFLOW – Platform Expansion

*Intranasal Spray for
Oesophageal Motility Disorders (OMD)*

- ▶ HREC-approved study; initiation pending hospital contract sign-off
- ▶ First platform application beyond ED, in gastrointestinal disease
- ▶ Capital prioritised to lead program

Portfolio Expansion

KYZATREX®

*Oral Therapy for Testosterone
Deficiency*

- ▶ Exclusive pilot commercialisation agreement with Marius Pharmaceuticals (US)
- ▶ FDA-approved oral testosterone therapy; initial Australian patient access via the TGA Special Access Scheme
- ▶ Six-month evaluation period, with a right to negotiate an exclusive Australian licence

Strategic Investment

LevOmega

Nature-Identical omega-3 Products

- ▶ 43% equity interest
- ▶ Separate development pathway and capital structure; LTR capital prioritised for core intranasal programs

Key Milestones

Completed milestones → current execution → next major value inflection points




Cash \$19.6M | Avg. quarterly net operating outflow \$2.8M¹ | Zero debt |
Funded to deliver near-term U.S. commercial, clinical and regulatory value inflection points

Source: Appendix 4C for the quarter ended 30 June 2026. 1) Average net operating cash outflow per quarter over the twelve months to 30 June 2026. June 2026 quarter net operating outflow: \$4.4M. Cash figures in Australian Dollars.

Making headlines in FY26

Throughout FY26, LTR Pharma's clinical and commercial milestones were reported across Australian business and investor media, including Stockhead, The Australian, Ausbiz, Small Caps, and biotech publications.

SPONTAN's science reached clinicians directly in FY26: published in the European Journal of Pharmaceutical Sciences, delivered from the podium at WMSM 2026 in Porto, Portugal, and presented to urologists at APCC Sydney and GPs nationally.



Board of Directors

Seasoned leadership driving innovation and growth in healthcare



Mr. LEE RODNE (Executive Chairman)

- ▲ Healthcare entrepreneur and executive with 25+ years' experience building, commercialising and scaling healthcare and technology businesses across public and private markets.
- ▲ Former CEO and Managing Director of Allied Medical, a Fortescue Metals Group spin-out (later Admedus Ltd, now Anteris Technologies), which he led from an approximately \$800k valuation to a peak valuation of approximately \$250m.
- ▲ Track record commercialising medical products across Australia, North America, Europe and Asia, including experience in nasal drug-delivery products.

Ms. MAJA MCGUIRE (Independent Non-Executive Director)

- ▲ Over 15 years' experience advising and leading ASX-listed companies as an Australian-qualified lawyer, spanning non-executive chair and director roles, general counsel and company secretary positions, and top-tier private practice.
- ▲ Former executive roles with Anteris Technologies (ASX: AVR) and Alexium International (ASX: AJC).
- ▲ Director of ReNerve Ltd (ASX: RNV), TechGen Metals Ltd (ASX: TG1) and Kuniko Ltd (ASX: KNI).
- ▲ Chair of the Audit and Risk Committee.

Dr. JULIAN CHICK (Independent Non-Executive Director)

- ▲ Over 20 years' experience in senior management and board positions, including ASX-listed Avexa and Admedus.
- ▲ CEO of ReNerve Ltd (ASX: RNV); director of MABT Pty Ltd and LTR Medical Pty Ltd.
- ▲ Eight years' investment banking experience and a former analyst role reviewing healthcare and biotechnology investment opportunities for private equity and venture capital investors.
- ▲ Chair of the Nomination and Remuneration Committee.

Global Team, Strategic US Presence

Experienced leadership across key markets

Executive Team

Executive Chairman | Lee Rodne

Over 25 years in healthcare and tech sectors in both public ASX and private enterprises.

Chief Financial Officer | Jacques Schipper

Over 15 years of experience in finance, commercial management and controller roles.

Chief Operating Officer | Peter McLennan

Over 15 years of experience in investment banking, investor relations and operations.

Chief Medical Officer | Prof Geoffrey Strange

Over 20 years of experience in the pharmaceutical and medical industries as a senior executive and medical researcher.

Chief Commercial Officer | Danny Zanardo

Over 25 years of commercial experience in the Australian and global healthcare sectors across pharmaceuticals and medical devices.

Program Director | Anthony Bishop

Over 30 years of experience in all aspects of pharmaceutical, medical device and diagnostic development for global markets.

US TEAM

General Manager & Business Development US | Tom Riester

Over 25 years of experience in sales and management in digital health, medical device and precision medicine.

Vice President – US Sales & Marketing | Mike Sweeting

Over 30 years in the pharmaceutical industry in US commercial sales and market access.

Vice President Operations & Clinical Development | Dr Monil Shah

Over 20 years of pharmaceutical and biotechnology industry experience in drug development.

Vice President, Global Regulatory Affairs | Kip Vought

Over 25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.

Corporate Snapshot

As of 22 October 2026

ASX code	LTP
Shares on issue	182.27M
Market capitalisation	\$85.66M
Cash and cash equivalents (30 June 2026)	A\$19.6M
Debt	Nil
Top 20 shareholders	45.73%